Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Biological Autoimmune Therapeutics


NEW YORK, Nov. 15, 2018 /PRNewswire/ -- The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration.  Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward user acceptance and designed-in usability. The influence of biosimilars on as-supplied packaging strategies is yet to be determined, but the need for product differentiation in an increasingly crowded market segment will make product packaging a key competitive factor.


Read the full report: https://www.reportlinker.com/p05621767

What You Will Learn
- What are the approved biological drugs indicated for autoimmune conditions, what is the as-supplied packaging, and who markets them?
- What are the major factors driving the growth of biological drugs for treating autoimmunity?
- What is the size of the market biological autoimmune therapeutics drugs today, who are the market share leaders, and what will it be in 2022?
- How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
- What are the essential design factors, technologies and market development issues for biological autoimmune drugs?
- What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?

Read the full report: https://www.reportlinker.com/p05621767

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 22:03
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...



News published on and distributed by: